Business
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal.
About this update from Gc Biopharma Corp.
[{"type":"text","content":"YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The research findings, detailing the role of N-glycosylation in lysosomal targeting, have been published in the International Journal of Biological Macromolecules, a prestigious SCIE-indexed journal.","length":490,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/GC Biopharma)","displaySize":"","headline":null,"caption":"(PRNewsfoto/GC Biopharma)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/4b834899abdf3d99fcde8560d438cc9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/B0c2J77qVeMlBCJvcjoKKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/4b834899abdf3d99fcde8560d438cc9a","width":400,"height":400}},"href":"https://mma.prnewswire.com/media/1888566/GC_Biopharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Hunter syndrome (MPS II) is a rare genetic disorder caused by mutations in the iduronate-2-sulfatase (IDS) gene, resulting in a deficiency of the IDS enzyme, which is essential for the degradation of glycosaminoglycans (GAGs). This deficiency leads to the progressive accumulation of GAG within lysosomes, causing a range of symptoms. Thus, effective treatment relies on delivering the therapeutic enzyme to lysosomes to facilitate GAG breakdown.","length":446,"tagName":"p"},{"type":"text","content":"For effective lysosomal targeting, the N-glycan structures of the therapeutic enzyme must contain mannose-6-phosphate (M6P). M6P acts as a targeting signal, guiding the enzyme to bind to cells, facilitating its uptake and delivery into lysosomes to degrade GAGs.","length":262,"tagName":"p"},{"type":"text","content":"The research utilized high-resolution Orbitrap mass spectrometry to analyze the site-specific N-glycan structures of idursulfase beta (Hunterase). A total of 42 N-glycan structures were identified, with two sites, Asn221 and Asn255, found to be predominantly modified with bis-mannose-6-phosphate (bis-M6P), a structure containing two phosphate groups. The research team ...